Abstract | BACKGROUND: DESIGN AND METHODS: To further clarify the prognostic impact of parameters such as FLT3 mutations, we comprehensively characterized the relation between genetic features and outcome in 147 patients (aged 19.7-86.3 years) with acute promyelocytic leukemia. RESULTS: Internal tandem duplications of the FLT3 gene (FLT3-ITD) were detected in 47/147 (32.0%) and tyrosine kinase domain mutations (FLT3-TKD) in 19/147 (12.9%) patients. FLT3-ITD or FLT3-TKD mutation status did not have a significant prognostic impact, whereas FLT3-ITD mutation load, as defined by a mutation/wild-type ratio of less than 0.5 was associated with trends to a better 2-year overall survival rate (86.7% versus 72.7%; P=0.075) and 2-year event-free survival rate (84.5% versus 62.1%, P=0.023) compared to the survival rates of patients with a ratio of 0.5 or more. Besides the t(15;17), an additional chromosomal abnormality was detected in 57 of 147 cases and did not show a significant impact on survival. White blood cell counts of 10×10(9)/L or less versus more than 10×10(9)/L were associated with a better 2-year overall survival rate (88.3% versus 69.4%, respectively; P=0.015), as was male sex (P=0.040). In multivariate analysis, only higher age had a significant adverse impact. CONCLUSIONS: Prospective trials should further investigate the clinical impact of the FLT3-ITD/wild-type mutation load aiming to evaluate whether this parameter might be included in risk stratification in patients with acute promyelocytic leukemia.
|
Authors | Susanne Schnittger, Ulrike Bacher, Claudia Haferlach, Wolfgang Kern, Tamara Alpermann, Torsten Haferlach |
Journal | Haematologica
(Haematologica)
Vol. 96
Issue 12
Pg. 1799-807
(Dec 2011)
ISSN: 1592-8721 [Electronic] Italy |
PMID | 21859732
(Publication Type: Clinical Trial, Comparative Study, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Oncogene Proteins, Fusion
- promyelocytic leukemia-retinoic acid receptor alpha fusion oncoprotein
- Tretinoin
- FLT3 protein, human
- fms-Like Tyrosine Kinase 3
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(administration & dosage)
- Chromosomes, Human, Pair 15
(genetics)
- Chromosomes, Human, Pair 17
(genetics)
- Disease-Free Survival
- Female
- Humans
- Leukemia, Promyelocytic, Acute
(drug therapy, genetics, mortality)
- Male
- Middle Aged
- Oncogene Proteins, Fusion
(genetics)
- Survival Rate
- Translocation, Genetic
- Tretinoin
(administration & dosage)
- fms-Like Tyrosine Kinase 3
(genetics)
|